Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

NCT00941863 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma

Interventions

DRUG: Sorafenib 100 mg (50-mg tablet)
DRUG: Sorafenib 200 mg (50-mg tablet)
DRUG: Sorafenib 400 mg (50-mg tablet)
DRUG: Sorafenib 400 mg (200-mg tablet)
DRUG: Sorafenib 400 mg (Expansion)

Sponsor

Bayer

Collaborators

[object Object]